0	14	Glucocorticoid	glucocorticoid	NN
15	22	hormone	hormone	NN
23	34	suppression	suppression	NN
35	37	of	of	IN
38	43	human	human	JJ
44	63	neutrophil-mediated	neutrophil-mediated	JJ
64	69	tumor	tumor	NN
70	74	cell	cell	NN
75	85	cytostasis	cytostasis	NN
85	86	.	.	.

88	90	In	in	IN
91	94	the	the	DT
95	102	present	present	JJ
103	108	study	study	NN
108	109	,	,	,
110	112	we	we	PRP
113	117	have	have	VBP
118	130	investigated	investigate	VBN
131	134	the	the	DT
135	141	effect	effect	NN
142	144	of	of	IN
145	159	glucocorticoid	glucocorticoid	NN
160	168	hormones	hormone	NNS
169	171	on	on	IN
172	191	neutrophil-mediated	neutrophil-mediated	JJ
192	197	tumor	tumor	NN
198	202	cell	cell	NN
203	213	cytostasis	cytostasis	NN
214	217	and	and	CC
218	223	found	find	VBD
224	228	that	that	IN
229	243	hydrocortisone	hydrocortisone	NN
244	247	and	and	CC
248	249	a	a	DT
250	259	synthetic	synthetic	JJ
260	267	hormone	hormone	NN
267	268	,	,	,
269	282	dexamethasone	dexamethasone	NN
283	284	(	(	(
284	287	Dex	Dex	NNP
287	288	)	)	)
288	289	,	,	,
290	299	inhibited	inhibit	VBD
300	310	cytostasis	cytostasis	NN
311	313	in	in	IN
314	317	the	the	DT
318	326	presence	presence	NN
327	329	or	or	CC
330	337	absence	absence	NN
338	340	of	of	IN
341	346	tumor	tumor	NN
347	355	necrosis	necrosis	NN
356	368	factor-alpha	factor-alpha	NN
368	369	.	.	.

370	373	The	the	DT
374	380	effect	effect	NN
381	383	of	of	IN
384	387	Dex	Dex	NNP
388	391	was	be	VBD
392	402	completely	completely	RB
403	411	reversed	reverse	VBN
412	414	by	by	IN
415	416	a	a	DT
417	431	glucocorticoid	glucocorticoid	NN
432	440	receptor	receptor	NN
441	451	antagonist	antagonist	NN
451	452	,	,	,
453	460	RU38486	RU38486	NNP
460	461	.	.	.

462	464	To	to	TO
465	472	clarify	clarify	VB
473	476	the	the	DT
477	487	underlying	underlying	JJ
488	498	mechanisms	mechanism	NNS
498	499	,	,	,
500	502	we	we	PRP
503	511	examined	examine	VBD
512	519	effects	effect	NNS
520	522	of	of	IN
523	526	Dex	Dex	NNP
527	529	on	on	IN
530	533	the	the	DT
534	541	binding	binding	NN
542	549	avidity	avidity	NN
550	552	of	of	IN
553	558	beta2	beta2	NN
559	567	integrin	integrin	NN
568	570	on	on	IN
571	574	the	the	DT
575	585	neutrophil	neutrophil	NN
586	593	surface	surface	NN
594	597	and	and	CC
598	601	how	how	WRB
602	607	these	these	DT
608	613	might	might	NN
614	616	in	in	IN
617	621	turn	turn	NN
622	628	affect	affect	VBP
629	648	neutrophil-to-tumor	neutrophil-to-tumor	NN
649	653	cell	cell	NN
654	661	binding	binding	NN
661	662	.	.	.

663	666	Dex	Dex	NNP
667	670	was	be	VBD
671	676	found	find	VBN
677	679	to	to	TO
680	687	inhibit	inhibit	VB
688	693	these	these	DT
694	704	neutrophil	neutrophil	NN
705	715	properties	property	NNS
715	716	,	,	,
717	720	and	and	CC
721	728	RU38486	RU38486	NNP
729	739	completely	completely	RB
740	750	suppressed	suppress	VBD
751	755	both	both	DT
756	761	forms	form	NNS
762	764	of	of	IN
765	768	Dex	Dex	NNP
769	779	inhibition	inhibition	NN
779	780	.	.	.

781	786	Taken	take	VBN
787	795	together	together	RB
795	796	,	,	,
797	800	our	our	PRP$
801	809	findings	finding	NNS
810	817	suggest	suggest	VBP
818	822	that	that	IN
823	837	glucocorticoid	glucocorticoid	NN
838	845	hormone	hormone	NN
846	856	inhibition	inhibition	NN
857	859	of	of	IN
860	879	neutrophil-mediated	neutrophil-mediated	JJ
880	885	tumor	tumor	NN
886	890	cell	cell	NN
891	901	cytostasis	cytostasis	NN
902	904	is	be	VBZ
905	907	at	at	IN
908	913	least	least	JJS
914	923	partially	partially	RB
924	927	due	due	JJ
928	930	to	to	TO
931	932	a	a	DT
933	941	lowering	lowering	NN
942	944	of	of	IN
945	948	the	the	DT
949	955	ligand	ligand	NN
956	963	binding	binding	NN
964	971	avidity	avidity	NN
972	974	of	of	IN
975	980	beta2	beta2	NN
981	989	integrin	integrin	NN
990	992	on	on	IN
993	996	the	the	DT
997	1007	neutrophil	neutrophil	NN
1008	1015	surface	surface	NN
1015	1016	.	.	.